Vanguard Capital Management’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$122M Buy
7,230,441
+1,495,957
+26% +$22.4M ﹤0.01% 1405
2026
Q2
$83.6M Buy
5,734,484
+22,682
+0.4% +$402K ﹤0.01% 1657
2026
Q1
$108M Buy
+5,711,802
New +$92.4M ﹤0.01% 1431

Other funds holding SMMT

Vanguard Capital Management's SMMT Position: Q3 2026 in Review

Vanguard Capital Management increased its Summit Therapeutics (SMMT) stake by 26% in Q3 2026, buying an estimated $22.4M and bringing the position to 7,230,441 shares worth $122M. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

Vanguard Capital Management first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Vanguard Capital Management held 7,230,441 shares of Summit Therapeutics worth $122M as of Q3 2026.
  • Vanguard Capital Management bought 1,495,957 Summit Therapeutics shares in Q3 2026, an estimated $22.4M.
  • Summit Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1405 holding.
  • Vanguard Capital Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.